Anthem Bioscienc

Q: Is Anthem Bioscienc overvalued or undervalued?

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

Q: How has been the historical performance of Anthem Bioscienc?

Answer:The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.Breakdown:Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Q: Should I buy, sell or hold Anthem Biosciences Ltd?

Based on the latest information about Anthem Biosciences Ltd, it appears that the recommendation leans towards selling. The company has reported negative results for the December quarter, with a significant decline in profit before tax (PBT) and profit after tax (PAT), along with the lowest net sales recorded. The valuation seems high, given the price-to-book ratio of 15.4, especially considering the return on equity (ROE) of 17.7%.While there are some positive aspects, such as high management efficiency and being net-debt free, the recent financial performance raises concerns. Additionally, although institutional investors have increased their stake, which could indicate confidence in the company's long-term potential, the immediate financial results suggest caution.In summary, given the recent negative performance indicators and high valuation, it may be prudent to consider selling your shares in Anthem Biosciences Ltd.

Market Cap: Mid Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE0CZ201020
NSEID: ANTHEM
BSEID: 544449
View on NSE | View on BSE

INR

783.60

-3.5 (-0.44%)

BSENSE

May 20

BSE+NSE Vol: 16.48 lacs

Access older stock analysis version

Results Declared: Anthem Bioscienc has declared results on 19 May 2026! Click here to unlock the latest financial performance

Mojo Score Change: Anthem Bioscienc has changed its score on 18 May 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

16.48 lacs (718.91%) Volume

Shareholding (Mar 2026)

FII

1.28%

Held by 37 FIIs

DII

11.55%

Held by 26 DIIs

Promoter

74.68%

Is Anthem Bioscienc overvalued or undervalued?

01-Sep-2025

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

View full answer

How has been the historical performance of Anthem Bioscienc?

09-Nov-2025

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

View full answer

When is the next results date for Anthem Biosciences Ltd?

13-May-2026

The next results date for Anthem Biosciences Ltd is 19 May 2026.

View full answer

Which are the latest news on Anthem Bioscienc?

19-May-2026

Anthem Biosciences Downgraded to Sell Amid Technical Weakness and Financial Setbacks
Anthem Biosciences Ltd’s Mixed Week: -0.13% Price Change Amid Technical Shifts

Should I buy, sell or hold Anthem Biosciences Ltd?

19-May-2026

Why is Anthem Biosciences Ltd falling/rising?

20-May-2026

As of 19-May, Anthem Biosciences Ltd's stock price is Rs 787.10, down 0.36%, and has underperformed its sector today. Despite a strong long-term growth of 20.90% year-to-date, recent negative financial results and declining investor interest are impacting its current performance.

As of 19-May, Anthem Biosciences Ltd's stock price is currently at Rs 787.10, reflecting a decrease of Rs 2.85 or 0.36%. The stock has underperformed its sector by 1.35% today, despite opening with a gain of 2.05% and reaching an intraday high of Rs 814, which indicates some initial positive momentum that was not sustained throughout the trading session. The stock's performance over the past week shows a decline of 1.65%, contrasting with a 0.86% increase in the Sensex, suggesting that the stock is not keeping pace with broader market trends. However, over the past month, the stock has shown a positive return of 9.29%, while the Sensex has fallen by 4.19%, indicating a stronger performance relative to the market during that period. Despite these positive trends in the longer term, with a year-to-date increase of 20.90% compared to a 11.76% decline in the Sensex, there are significant concerns affecting the stock's current price. Recent financial results have shown negative trends, including a 24.2% decrease in profit before tax and a 14.1% decrease in profit after tax compared to the previous four-quarter average. Additionally, net sales have reached their lowest at Rs 423.15 crore, which raises concerns about the company's short-term financial health. Moreover, there has been a notable decline in investor participation, with delivery volume dropping by 66.64% against the five-day average, indicating reduced interest from investors. Although institutional investors have increased their stake by 3.87%, the overall market sentiment appears to be cautious, particularly in light of the company's high valuation metrics, such as a Price to Book Value of 15.4, which may be perceived as expensive given the current financial performance. In summary, while Anthem Biosciences Ltd has shown strong long-term growth and has a net-debt-free status, the recent negative financial results and declining investor participation are contributing to the stock's current downward movement.

View full answer

Compare Anthem Bioscienc with Similar Stocks

Abbott India Ipca Labs Alkem Lab

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With ROE of 17.7, it has a Very Expensive valuation with a 15.4 Price to Book Value

Over the past year, while the stock has generated a return of NA, its profits have risen by 35%

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 44,016 Cr (Mid Cap)

P/E

88.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.34

Return on Equity

17.74%

Price to Book

15.43

Revenue and Profits:

Net Sales:

611 Cr

(Quarterly Results - Mar 2026)

Net Profit:

190 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

15.13%

6 Months

20.96%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Anthem Bioscienc for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Anthem Biosciences Downgraded to Sell Amid Technical Weakness and Financial Setbacks

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 18 May 2026. This shift reflects a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns, despite some positive long-term fundamentals and institutional interest.

Read full news article

Anthem Biosciences Ltd’s Mixed Week: -0.13% Price Change Amid Technical Shifts

Key Events This Week

11 May: Technical momentum shifts to mildly bullish amid market outperformance

12 May: Upgrade to Hold by MarketsMOJO; sideways technical trend emerges

13 May: Continued technical momentum shift with strong returns

15 May: Sharp decline of 4.27% on low volume closes the week

Week Open

Rs.784.55

Week Clos...

Read full news article

When is the next results date for Anthem Biosciences Ltd?

The next results date for Anthem Biosciences Ltd is scheduled for 19 May 2026....

Read full news article

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

12-May-2026 | Source : BSE

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that an Earnings Conference Call to discuss the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2026 is scheduled on Wednesday May 20 2026 at 11:00 AM IST/ 01:30 AM USA / 06:30 AM UK / 01:30 PM SGT/HKT.

Board Meeting Intimation for Approve The Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended March 31 2026 And To Consider Recommendation Of Final Dividend

12-May-2026 | Source : BSE

Anthem Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 inter alia to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2026 and to consider the recommendation of final dividend if any for the financial year ended March 31 2026 amongst other routine matters.

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

30-Apr-2026 | Source : BSE

Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No.	Particulars	Details
1	Name of Company	Anthem Biosciences Ltd
2	CIN NO.	U24233KA2006PLC039703
3	Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)	2.96
4	Highest Credit Rating during the previous FY	NA
4a	Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)	Not Applicable
5	Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework	BSE

We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No

Name of the Company Secretary: Divya Prasad
Designation: Company Secretary and Compliance Officer
EmailId: divya.p@anthembio.com

Name of the Chief Financial Officer: Mohammed Gawir Baig
Designation: Chief Financial Officer
EmailId: gawir.b@anthembio.com

Date: 30/04/2026

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

29.80%

EBIT Growth (5y)

44.32%

EBIT to Interest (avg)

56.77

Debt to EBITDA (avg)

0.16

Net Debt to Equity (avg)

-0.25

Sales to Capital Employed (avg)

0.62

Tax Ratio

28.85%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

12.83%

ROCE (avg)

32.59%

ROE (avg)

19.93%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

15.43

EV to EBIT

70.47

EV to EBITDA

62.50

EV to Capital Employed

22.96

EV to Sales

23.39

PEG Ratio

Dividend Yield

ROCE (Latest)

32.59%

ROE (Latest)

17.74%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 27 Schemes (10.12%)

FIIs

Held by 37 FIIs (1.28%)

Promoter with highest holding

Ajay Bhardwaj (42.53%)

Highest Public shareholder

Portsmouth Technologies Llc . (2.74%)

Individual Investors Holdings

9.38%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 39.83% vs -24.56% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 88.79% vs -43.50% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "582.50",
          "val2": "416.58",
          "chgp": "39.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "266.99",
          "val2": "163.05",
          "chgp": "63.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.58",
          "val2": "1.13",
          "chgp": "39.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.97",
          "val2": "-24.98",
          "chgp": "103.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "211.67",
          "val2": "112.12",
          "chgp": "88.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "45.84%",
          "val2": "39.14%",
          "chgp": "6.70%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,090.24",
          "val2": "863.40",
          "chgp": "26.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "421.08",
          "val2": "324.04",
          "chgp": "29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.84",
          "val2": "5.20",
          "chgp": "-26.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "346.77",
          "val2": "255.63",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.62%",
          "val2": "37.53%",
          "chgp": "1.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,506.82",
          "val2": "1,361.66",
          "chgp": "10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "584.13",
          "val2": "490.89",
          "chgp": "18.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.97",
          "val2": "6.99",
          "chgp": "-28.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "458.89",
          "val2": "383.62",
          "chgp": "19.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.77%",
          "val2": "36.05%",
          "chgp": "2.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 15.17% vs 29.96% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 31.14% vs 22.86% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,124.33",
          "val2": "1,844.55",
          "chgp": "15.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "833.81",
          "val2": "670.83",
          "chgp": "24.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.89",
          "val2": "10.33",
          "chgp": "-33.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.39",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "591.79",
          "val2": "451.26",
          "chgp": "31.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "39.25%",
          "val2": "36.37%",
          "chgp": "2.88%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

582.50

416.58

39.83%

Operating Profit (PBDIT) excl Other Income

266.99

163.05

63.75%

Interest

1.58

1.13

39.82%

Exceptional Items

0.97

-24.98

103.88%

Standalone Net Profit

211.67

112.12

88.79%

Operating Profit Margin (Excl OI)

45.84%

39.14%

6.70%

Values in Rs Cr.

Compare with Peers

Net Sales
QoQ Growth in quarter ended Mar 2026 is 39.83% vs -24.56% in Dec 2025

Standalone Net Profit
QoQ Growth in quarter ended Mar 2026 is 88.79% vs -43.50% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

1,090.24

863.40

26.27%

Operating Profit (PBDIT) excl Other Income

421.08

324.04

29.95%

Interest

3.84

5.20

-26.15%

Exceptional Items

0.00

Standalone Net Profit

346.77

255.63

35.65%

Operating Profit Margin (Excl OI)

38.62%

37.53%

1.09%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,506.82

1,361.66

10.66%

Operating Profit (PBDIT) excl Other Income

584.13

490.89

18.99%

Interest

4.97

6.99

-28.90%

Exceptional Items

-24.98

0.00

Standalone Net Profit

458.89

383.62

19.62%

Operating Profit Margin (Excl OI)

38.77%

36.05%

2.72%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

2,124.33

1,844.55

15.17%

Operating Profit (PBDIT) excl Other Income

833.81

670.83

24.30%

Interest

6.89

10.33

-33.30%

Exceptional Items

-24.39

0.00

Consolidate Net Profit

591.79

451.26

31.14%

Operating Profit Margin (Excl OI)

39.25%

36.37%

2.88%

Values in Rs Cr.

Compare with Peers

Net Sales
YoY Growth in year ended Mar 2026 is 15.17% vs 29.96% in Mar 2025

Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 31.14% vs 22.86% in Mar 2025

All Annual Results

Company CV

About Anthem Biosciences Ltd

Anthem Biosciences Ltd

Mid Cap

Pharmaceuticals & Biotechnology

Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited", dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to "Anthem Biosciences Limited" and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.